Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Oct 17, 2024

BUY
$17.75 - $41.6 $14 Million - $32.8 Million
789,645 New
789,645 $31.3 Million
Q1 2024

Aug 16, 2024

BUY
$17.75 - $41.6 $1.26 Million - $2.95 Million
70,904 Added 9.87%
789,645 $31.3 Million
Q1 2024

May 15, 2024

BUY
$17.75 - $41.6 $1.26 Million - $2.95 Million
70,904 Added 9.87%
789,645 $31.3 Million
Q4 2023

Aug 16, 2024

BUY
$8.54 - $20.22 $6.14 Million - $14.5 Million
718,741 New
718,741 $13.7 Million
Q4 2023

Feb 13, 2024

BUY
$8.54 - $20.22 $5.68 Million - $13.5 Million
665,268 Added 1244.12%
718,741 $13.7 Million
Q3 2023

Nov 15, 2023

BUY
$10.13 - $13.98 $33,114 - $45,700
3,269 Added 6.51%
53,473 $612,000
Q2 2023

Aug 14, 2023

BUY
$6.84 - $11.91 $152,463 - $265,473
22,290 Added 79.85%
50,204 $516,000
Q1 2023

May 15, 2023

BUY
$7.0 - $8.75 $72,471 - $90,588
10,353 Added 58.95%
27,914 $215,000
Q4 2022

Feb 14, 2023

BUY
$5.45 - $7.35 $32,694 - $44,092
5,999 Added 51.89%
17,561 $129,000
Q3 2022

Nov 14, 2022

SELL
$6.89 - $9.39 $11,278 - $15,371
-1,637 Reduced 12.4%
11,562 $84,000
Q2 2022

Oct 27, 2022

BUY
$6.71 - $9.52 $26,316 - $37,337
3,922 Added 42.28%
13,199 $112,000
Q2 2022

Aug 15, 2022

BUY
$6.71 - $9.52 $26,316 - $37,337
3,922 Added 42.28%
13,199 $112,000
Q1 2022

Oct 27, 2022

SELL
$6.41 - $13.89 $25,140 - $54,476
-3,922 Reduced 29.71%
9,277 $83,000
Q1 2022

May 13, 2022

BUY
$6.41 - $13.89 $846 - $1,833
132 Added 1.44%
9,277 $83,000
Q4 2021

Feb 14, 2022

BUY
$10.41 - $13.95 $66,738 - $89,433
6,411 Added 234.49%
9,145 $127,000
Q3 2021

Nov 15, 2021

BUY
$8.19 - $11.31 $22,391 - $30,921
2,734 New
2,734 $28,000

Others Institutions Holding ALPN

About ALPINE IMMUNE SCIENCES, INC.


  • Ticker ALPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,006,700
  • Description
  • Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...
More about ALPN
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.